Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 TO 49 YEARS OF AGE IN INDIA

NCT05329259 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05329259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05329259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 TO 49 YEARS OF AGE IN INDIA
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
October 6, 2022
Completion date
November 30, 2022
Enrollment
200 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal disease